MX2022006364A - Tratamiento genico con apoe. - Google Patents
Tratamiento genico con apoe.Info
- Publication number
- MX2022006364A MX2022006364A MX2022006364A MX2022006364A MX2022006364A MX 2022006364 A MX2022006364 A MX 2022006364A MX 2022006364 A MX2022006364 A MX 2022006364A MX 2022006364 A MX2022006364 A MX 2022006364A MX 2022006364 A MX2022006364 A MX 2022006364A
- Authority
- MX
- Mexico
- Prior art keywords
- apoe
- geneic
- treatment
- coding
- mammalian apolipoprotein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962939999P | 2019-11-25 | 2019-11-25 | |
| PCT/US2020/070822 WO2021108809A1 (en) | 2019-11-25 | 2020-11-25 | Apoe gene therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006364A true MX2022006364A (es) | 2022-06-22 |
Family
ID=73857283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006364A MX2022006364A (es) | 2019-11-25 | 2020-11-25 | Tratamiento genico con apoe. |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4065600A1 (https=) |
| JP (2) | JP2023502515A (https=) |
| KR (1) | KR20220107243A (https=) |
| CN (1) | CN114829390A (https=) |
| AU (1) | AU2020391518B2 (https=) |
| BR (1) | BR112022010065A2 (https=) |
| CA (1) | CA3162761A1 (https=) |
| IL (1) | IL293116A (https=) |
| MX (1) | MX2022006364A (https=) |
| NZ (1) | NZ789753A (https=) |
| WO (1) | WO2021108809A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| KR20230112672A (ko) * | 2020-11-25 | 2023-07-27 | 프리베일 테라퓨틱스, 인크. | 신경변성 질환을 위한 유전자 요법 |
| EP4508213A1 (en) * | 2022-04-12 | 2025-02-19 | uniQure biopharma B.V. | Nucleic acid regulation of apoe |
| WO2023198702A1 (en) * | 2022-04-12 | 2023-10-19 | Uniqure Biopharma B.V. | Nucleic acid regulation of c9orf72 |
| EP4551711A1 (en) * | 2022-07-08 | 2025-05-14 | Cornell University | Methods and pharmaceutical compositions for the treatment and the prevention of alzheimers disease |
| WO2025213111A2 (en) * | 2024-04-05 | 2025-10-09 | Cornell University | Aav expression of mirna to suppress human apoe mrna |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| AU4198793A (en) | 1992-07-24 | 1994-01-27 | Takeda Chemical Industries Ltd. | Microparticle preparation and production thereof |
| FR2695563B1 (fr) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
| US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
| US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
| ATE163230T1 (de) | 1993-03-09 | 1998-02-15 | Epic Therapeutics Inc | Makromolekulare mikropartikel und verfahren zu ihrer herstellung |
| US5603960A (en) | 1993-05-25 | 1997-02-18 | O'hagan; Derek T. | Preparation of microparticles and method of immunization |
| US6913767B1 (en) | 1993-10-25 | 2005-07-05 | Genentech, Inc. | Compositions for microencapsulation of antigens for use as vaccines |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| CA2267930A1 (en) | 1996-10-09 | 1998-04-16 | Nobuyuki Takechi | A method for producing a microparticle |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| US6884435B1 (en) | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| US6406719B1 (en) | 1998-05-13 | 2002-06-18 | Microbiological Research Authority | Encapsulation of bioactive agents |
| GB9810236D0 (en) | 1998-05-13 | 1998-07-08 | Microbiological Res Authority | Improvements relating to encapsulation of bioactive agents |
| US6264987B1 (en) | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
| WO2007041190A2 (en) | 2005-09-30 | 2007-04-12 | The University Of Iowa Research Foundation | Polymer-based delivery system for immunotherapy of cancer |
| US9572894B2 (en) | 2010-10-18 | 2017-02-21 | The University Of Iowa Research Foundation | Biodegradable particulate formulations |
| EP2673635A4 (en) | 2011-02-07 | 2015-08-12 | Neotope Biosciences Ltd | IMMUNOTHERAPY THROUGH APOE |
| WO2012115806A1 (en) | 2011-02-24 | 2012-08-30 | University Of Iowa Research Foundation | New biodegradable polymers with sulfenamide bonds for drug delivery applications |
| CN106890315B (zh) * | 2017-03-16 | 2019-09-06 | 北京热休生物技术有限公司 | Apo-e蛋白及其多肽在治疗与预防癌症中的应用 |
| JP7221275B2 (ja) * | 2017-08-03 | 2023-02-13 | ボイジャー セラピューティクス インコーポレイテッド | Ａａｖを送達するための組成物および方法 |
| CN109776665B (zh) * | 2019-02-02 | 2021-02-05 | 首都医科大学宣武医院 | 阿尔茨海默病新突变、其稳转细胞模型及医药用途 |
| CA3141988A1 (en) * | 2019-05-28 | 2020-12-03 | The General Hospital Corporation | Apoe antibodies, fusion proteins and uses thereof |
-
2020
- 2020-11-25 EP EP20828741.7A patent/EP4065600A1/en active Pending
- 2020-11-25 JP JP2022530164A patent/JP2023502515A/ja active Pending
- 2020-11-25 NZ NZ789753A patent/NZ789753A/en unknown
- 2020-11-25 WO PCT/US2020/070822 patent/WO2021108809A1/en not_active Ceased
- 2020-11-25 BR BR112022010065A patent/BR112022010065A2/pt unknown
- 2020-11-25 CN CN202080081724.7A patent/CN114829390A/zh active Pending
- 2020-11-25 IL IL293116A patent/IL293116A/en unknown
- 2020-11-25 CA CA3162761A patent/CA3162761A1/en active Pending
- 2020-11-25 MX MX2022006364A patent/MX2022006364A/es unknown
- 2020-11-25 AU AU2020391518A patent/AU2020391518B2/en active Active
- 2020-11-25 KR KR1020227021579A patent/KR20220107243A/ko active Pending
-
2025
- 2025-07-25 JP JP2025124433A patent/JP2025163078A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020391518B2 (en) | 2025-02-13 |
| NZ789753A (en) | 2026-02-27 |
| CA3162761A1 (en) | 2021-06-03 |
| KR20220107243A (ko) | 2022-08-02 |
| WO2021108809A1 (en) | 2021-06-03 |
| US20230044351A1 (en) | 2023-02-09 |
| CN114829390A (zh) | 2022-07-29 |
| JP2023502515A (ja) | 2023-01-24 |
| BR112022010065A2 (pt) | 2022-09-06 |
| JP2025163078A (ja) | 2025-10-28 |
| EP4065600A1 (en) | 2022-10-05 |
| AU2020391518A1 (en) | 2022-07-14 |
| IL293116A (en) | 2022-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006364A (es) | Tratamiento genico con apoe. | |
| BR112021015799A2 (pt) | Métodos para aumentar o crescimento em pacientes pediátricos com doença colestática do fígado | |
| BR112022000231A2 (pt) | Novos métodos | |
| CY1119023T1 (el) | Ενα χιμαιρικο πολυπεπτιδιο λεπτινης φωκιας - ανθρωπου με αυξημενη διαλυτοτητα | |
| BR112015012295A8 (pt) | Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer | |
| BR112014029933A2 (pt) | aparelho para teste de eletrodo | |
| BR112013009157A2 (pt) | polipeptídeos com atividade de permease | |
| BR112014008529A2 (pt) | il-6 humanizado e receptor de il-6 | |
| Yang et al. | Mutations in LMNA modulate the lamin A-Nesprin-2 interaction and cause LINC complex alterations | |
| BR112013029525A2 (pt) | proteínas de fusão terapêuticas | |
| MX369574B (es) | Anticuerpos humanos contra grem1. | |
| BR112015020274A2 (pt) | cepa possuindo produtividade melhorada de l-valina e método de produção de l-valina utilizando a mesma | |
| BR112017011642A2 (pt) | composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+. | |
| EA201390704A1 (ru) | Соединения, ингибирующие металлоферменты | |
| MX2016013600A (es) | Método para tratar adenocarcinoma de pulmón. | |
| MX350445B (es) | Analogos del factor b del complemento y sus usos. | |
| EA202092748A1 (ru) | Модуляторы экспрессии apol1 | |
| WO2020191041A3 (en) | Biomarkers for vitiligo | |
| BR112012019923A2 (pt) | métodos e composições para melhorar a função cognitiva | |
| BR112022007010A2 (pt) | Terapia gênica para doença de alzheimer | |
| EA201892438A1 (ru) | 6-АМИНОПИРИДИН-3-ИЛТИАЗОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγt | |
| BR112022013867A2 (pt) | Bactérias manipuladas para tratar distúrbios nos quais o oxalato é prejudicial | |
| PH12021551053A1 (en) | Modulators of irf5 expression | |
| EA201390876A1 (ru) | Соединения, ингибирующие металлоферменты | |
| MY197247A (en) | Recombinant glycoproteins and uses thereof |